International Gaucher Alliance Limited

International Gaucher Alliance Limited
Registered number:		06653373
Balance Sheet
as at 31 December 2024

Notes			2024			2023
£				£
Fixed assets
Intangible assets	8		6,980			12,216
Tangible assets	9		1,142			2,261
Investments	10		100			100
			8,222			14,577

Current assets
Debtors	12	51,382			35,147
Cash at bank and in hand		119,799			204,244
		171,181			239,391

Creditors: amounts falling due within one year	13	(10,340)			(36,575)

Net current assets			160,841			202,816

Total assets less current liabilities			169,063			217,393

Net assets			169,063			217,393

Total funds of the charity
Restricted Funds		14	-			16,142
Unrestricted Funds		14	169,063			201,251

Total charity funds			169,063			217,393

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.




Aimeé-Kate Bosch
Trustee
Approved by the board on 30 September 2025

International Gaucher Alliance Limited
Notes to the Accounts
for the year ended 31 December 2024


1	Accounting policies

	Basis of preparation
	The accounts have been prepared under the historical cost convention and in accordance with the Statement of Recommended Practice (SORP), Accounting and Reporting by Charities and FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard) and the Companies Act 2006. As such the charity has taken advantage of the exemption available not to present a Cash Flow statement. International Gaucher Alliance Limited meets the definition of a public benefit entity under FRS 102.

`	Departure from the Charities (Accounts and Reports) Regulations 2008
	The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair view'. This departure has involved following SORP 2015 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 (SORP 2005) which has since been withdrawn.

	Going concern
	The charitable activities are entirely dependent on continuing grant aid and voluntary donations. As a consequence, the going concern basis is dependent on the future flow of these uncertain funding streams. Accordingly, the Trustees have obtained forecasts and, after reviewing the financial forecasts for future periods to 31 December 2025, the Trustees are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements. Other than these matters, the Trustees are not aware of any material uncertainites about the charity's ability to continue as a going concern.

	Fund Accounting
	Funds held by the charity are either: Unrestricted funds are available for the use at the discretion of the trustees in furtherance of the general objectives of the charity. Designated funds are unrestricted funds earmarked by the trustees for a particular purpose. Restricted funds are subject to restrictions on their expenditure imposed by the donor or through the terms of appeal.

	Income
	Income received from subscriptions, donations, Gift Aid Tax and activities is measured at the fair value of the consideration received or receivable. Income is recognised when the charity has entitlement to the funds, any performance conditions attached the item of income have been met, it is probable that the income will be received and the amount can be reliably measured. Accruals are made for monies received on fund generating activities that were held during the financial year but received after the financial year end up to the date these financial statements were approved by the trustee/directors. Income received in advance of the provision of services is deferred until the criteria for income recognition are met.

	Donated services
	Donated services and facilities are included in the accounts on the basis of the value of the gift to the charity. All donated services and facilities are recognised as donation income when received, (provided the value of the gift can be measured reliably) and recognised as an expense with an equivalent value.

	Expenditure
	Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable tht a settlement will be required and the amount of the obligation can be measured reliably. Resources expended are included in the Statements of Financial Activities on an accrual basis, inclusive of any VAT which cannot be recovered. Where applicable they have been charged directly to the funds and activities to which they relate.

	Fixed Asset Investments
	Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

	Intangible fixed assets
	Website development costs are being written off in equal annual instalments over its estimated economic life of 5 years.


	Tangible fixed assets
	Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
	Plant and machinery					over 4 years

	Debtors
	Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

	Creditors
	Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

	Pensions
	Contributions to defined contribution plans are expensed in the period to which they relate.


2	Net income/(expenditure) for the year							2024		2023
£									£
	This is stated after charging:
	Depreciation and amortisation of owned fixed assets							1,119		1,141
	Trustees' and volunteers' remuneration							44,638		53,431
	Independent Examiner's remuneration							3,450		3,000
	Contributions to pension fund for employees							1,832		1,700


3	Donated goods, services and facilities							2024		2023
								Unrestricted funds		Unrestricted funds
£									£
	Included in donations and legacies:
	Donated goods and services							44,638		53,431
								44,638		53,431

	Directors and volunteers have made donations of their services to the company during the year to the value of £44,638 (2023: £53,431). Administration expenses include directors' and volunteers' fees for services donated to the company of £44,638 (2023: £53,431) and donations and legacies include donations by the directors and volunteers of £44,638 (2023: £53,431) in respect of their services to the company.

4	Staff costs							2024		2023
£									£

	Wages and salaries excluding trustees and key management personnel							46,011		40,197
	Social security costs							8,026		11,769
	Other pension costs							1,832		1,700
	Salaries and benefits paid to key management personnel							77,496		71,498
	Directors' and volunteers' fees for services donated to the charity							44,638		53,431
								178,003		178,595

	The cost to the charity of senior management personnel remuneration included the following:							2024		2023
£									£
	Gross wages and Employer's National Insurance contributions							83,312		80,110
	Contributions for the provision of money purchase pension							1,321		1,321

								2024		2023
	Numbers of such staff to whom benefits are accruing :							Number	Number
	Under money purchase pension schemes							1		1





5	Employees							2024		2023
Number									Number
	Average number of full time staff							1		1
	Average number of part time staff							2		2
	Average total number of staff							3		3

	The number of employees whose emoluments including taxable benefits but excluding
	employer's pension contributions fall into the following bands were :
								2024		2023
Number									Number

	£70,001 to £80,000							1		1

6	Remuneration and payments to volunteers and to Trustees and persons connected with them
								2024		2023
£									£
	Remuneration payable to trustees or connected persons
	Directors' and volunteers' fees for services donated to the charity							44,638		53,431

	Directors and volunteers have made donations of their services to the company during the year to the value of £44,638 (2023: £53,431). Administration expenses include directors' and volunteers' fees for services donated to the company of £44,638 (2023: £53,431) and donations and legacies include donations by the directors and volunteers of £44,638 (2023: £53,431) in respect of their services to the company.


7	Deferred income - Restricted funds			2024		2024		2023		2023
				Received		Deferred		Received		Deferred
				deferred in year		at year end		deferred in year		at year end
£					£		£		£
	Takeda Transitions grant			-		-		-		5,000
	Sanofi Outstanding research priorities			-		-		11,000		11,000
				-		-		11,000		16,000

	Deferred income is included in creditors and comprises funding specified by the funders as relating to specific periods and represent those parts of restricted funds which relate to periods subsequent to the accounting year end and are treated as grants in advance.


8	Intangible fixed assets									£
	Website development costs:

	Cost
	At 1 January 2024									24,900
	At 31 December 2024									24,900

	Amortisation
	At 1 January 2024									12,684
	Provided during the year									5,236
	At 31 December 2024									17,920

	Net book value
	At 31 December 2024									6,980
	At 31 December 2023									12,216

	Website development costs are being written off in equal annual instalments over its estimated economic life of 5 years.








9	Tangible fixed assets
								Plant and machinery etc		Total
£									£
	Cost
	At 1 January 2024							10,977		10,977
	At 31 December 2024							10,977		10,977

	Depreciation
	At 1 January 2024							8,716		8,716
	Charge for the year							1,119		1,119
	At 31 December 2024							9,835		9,835

	Net book value
	At 31 December 2024							1,142		1,142
	At 31 December 2023							2,261		2,261

10	Investments
Investments in
subsidiary
undertakings									Total
£									£
	Cost
	At 1 January 2024							100		100
	At 31 December 2024							100		100

	Historical cost
	At 1 January 2024							100
	At 31 December 2024							100

11	Subsidiary companies
	The name of the subsidiary undertaking is International Gardian Limited, registered in England & Wales with company number 12658731.
	The aggregate amount of the holding company's investment in its subsidiary is £100, which represents 100% of the issued ordinary share capital of the subsidiary. The subsidiary is controlled by the holding company by virtue of the power to appoint directors to the board of the subsidiary.
	The subsidiary's activities relate to those of the holding company in that the subsidiary is a trading enterprise engaging in trades similar to the charitable activities of the holding company.
								2024		2023
	A summary of the unaudited financial statements of the subsidiary is :							£	£

	Assets and Funds
	Aggregate amounts of assets /(liabilities)							22,629		3,246
	Aggregate amount of funds							22,629		3,246

	Profit and Loss
	Turnover							80,788		57,023
	Other income							139		1,035
	Expenses							(61,544)		(58,670)

	Net profit /(loss) for the year after tax							19,383		(612)

	The net profit/(loss) of the subsidiary is stated after including intergroup company expenditure of £22,756 (2023 - £28,498).

12	Debtors							2024		2023
£									£
	Amounts owed by group undertakings and undertakings in which the company has a participating interest							6,624		29,894
	Other debtors							44,758		5,253
								51,382		35,147


13	Creditors: amounts falling due within one year							2024		2023
£									£

	Trade creditors							629		13,231
	Deferred Income - Restricted funds							-		16,000
	Taxation and social security costs							3,171		3,364
	Other creditors							6,540		3,980
								10,340		36,575


14	Movement in Funds	As at 1 January 2024		Income		Expenditure		Transfers in/(out)		As at 31 December 2024
£			£		£		£		£
	Restricted funds
	Gene Therapy	60		-		-		(60)		-
	Sanofi work programme 2023	10,440		11,000		(6,215)		(15,225)		-
	Pfizer funding 2023-24	4,445		-		(4,980)		535		-
	Takeda Educating doctors	1,197		-		(1,197)		-		-
	Takeda transitions	-		5,000		(4,200)		(800)		-
	ISU sponsorship BGM	-		3,979		(3,963)		(16)		-
	Eli Lilly work programme 2024	-		15,000		(15,000)		-		-
	Eli Lilly BGM sponsorship	-		10,000		(10,016)		16		-
	Eli Lilly Educating and Empowering	-		5,000		(5,000)		-		-
	Sanofi work programme 2024	-		95,000		(86,984)		(8,016)		-
	Pfizer funding 2024	-		37,500		(37,501)		1		-
	Total restricted funds	16,142		182,479		(175,056)		(23,565)		-

	General fund	201,251		152,963		(208,716)		23,565		169,063
	Total unrestricted funds	201,251		152,963		(208,716)		23,565		169,063

	Total restricted and unrestricted funds	217,393		335,442		(383,772)		-		169,063

	Movement in Funds	As at 1 January 2023		Income		Expenditure		Transfers in/(out)		As at 31 December 2023
£			£		£		£		£
	Restricted funds
	Gene Therapy	60		-		-		-		60
	Sanofi work programme 2022	3,274		4,405		(3,274)		(4,405)		-
	Pfizer work programme 2022-23	5,235		20,800		(26,423)		388		-
	IWGDD	-		3,048		(3,610)		562		-
	Avrobio 2023	-		10,000		(10,000)		-		-
	Eli Lilly work programme 2023	-		30,000		(30,000)		-		-
	Sanofi work programme 2023	-		64,000		(60,231)		6,671		10,440
	Pfizer funding 2023-24	-		25,000		(20,555)		-		4,445
	Takeda Educating doctors	-		7,010		(5,813)		-		1,197
	Total restricted funds	8,569		164,263		(159,906)		3,216		16,142
										-
	General fund	178,287		231,396		(205,216)		(3,216)		201,251
	Total unrestricted funds	178,287		231,396		(205,216)		(3,216)		201,251

	Total restricted and unrestricted funds	186,856		395,659		(365,122)		-		217,393

	During the year ended 31 December 2024 transfers were made from unrestricted funds to cover deficits on Pfizer 2023-24 projects and Eli Lilly BGM sponsorship. A transfer was made from the Takeda Transitions fund to unrestricted funds to match costs recognised in unrestricted funds during 2024 related to this funding now paid. Transfers were made from the Sanofi work programme 2023 and 2024 funds to unrestricted funds following agreement with Sanofi to reallocate funds not spent on other IGA work programme projects without restriction. During the year the small brought forward balance on the Gene Therapy restricted fund was re-designated to the general fund as approved by the Trustees.





14	Movement in Funds (continued)
	During the year ended 31 December 2023 transfers were made from unrestricted funds to cover deficits on projects within the Sanofi work programme 2023, Pfizer work programme 2022 and IWGDD restricted funds. Funds were transferred to the Sanofi work programme in 2022 from unrestricted funds of £14,252 to cover anticipated deficits on projects in 2022. Of this amount, £4,405 was transferred back to unrestricted funds on completion of projects in 2023 when it was identified that final deficits on those projects were lower than anticipated.

	At 31 December 2024 the net assets of £153,356 were analysed between unrestricted funds of £153,356 and restricted funds of £nil.
	The purposes for which the funds are held by the charity are:

	Unrestricted funds:
	General fund	These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and, subject to charity legislation, are free from all restrictions on their use.

	Restricted funds:
	Gene Therapy	Funds received from Freeline for funding Gene Therapy work.
	Sanofi work programme 2022	Funds held for funds received from Sanofi for funding 2022 work programme.
	Sanofi work programme 2023	Funds held for funds received from Sanofi for funding 2023 work programme.
	Pfizer work programme 2022-23	Funds held for funds received from Pfizer for funding 2022-23 work programme.
	Pfizer work programme 2023-24	Funds held for funds received from Pfizer for funding 2023-24 work programme.
	IWGDD	Funds held for funds received from International Working Group on Gaucher Disease to support promotion and recruitment of patients and caregivers to the nGD registry.
	Avrobio 2023	Funds held for funds received from Avrobio for funding 2023 work programme.
	Eli Lilly work programme 2023	Funds held for funds received from Eli Lilly for funding 2023 work programme.
	Takeda Educating doctors	Funds held for funds received from Takeda for Education doctors work.
	Takeda transitions	Funds held for funds received from Takeda for Transitions prject.
	ISU sponsorship BGM	Funds received from ISUABXIS CO., LTD for sponsorship of the 2024 Biennial General Meeting.
	Eli Lilly work programme 2024	Funds held for funds received from Eli Lilly for funding 2024 work programme.
	Eli Lilly BGM sponsorship	Funds received from Eli Lilly for sponsorship of the 2024 Biennial General Meeting.
	Eli Lilly Educating and Empowering	Funds received from Eli Lilly for sponsorship of Educating and Empowering 2024 Global Advocates conference.
	Sanofi work programme 2024	Funds held for funds received from Sanofi for funding 2024 work programme.

15	Related party transactions

	During the year the company has recharged costs to its subsidiary International Gardian Limited as follows:
								2024		2023
£									£

	Administration fees							22,756		28,498

	Included in other debtors is £6,624 due from International Gardian Limited (2023:£29,894). Included in other creditors is £601 (2023: £601) owed to The Gauchers Association, Jeremy Manuel, the Honorary President of the Company is a director of The Gauchers Association Limited.
	During the year, staff costs of £15,707 (2023 - £23,226) recharged to its subsidiary, International Gardian Limited (“IGL”). These recharges are included within Income in Charitable Activities.
	During the year staff costs included £nil (2023:£1,243) relating to 50% of time spent on work done for its subsidiary International Gardian Limited ("IGL"). Administration fees included £nil relating to contractor costs incurred for IGL (2023: £2,367). These amounts have not been recharged to IGL as the charity agreed to fund 50% of staff and contractor time spent on IGL work for a period of 2 years from July 2021.

16	Controlling party

	The company is limited by guarantee and is under the control of its Trustees as a body.

17	Other information

	International Gaucher Alliance Limited is a private company limited by guarantee and is incorporated in England. It has no share capital. The liability of each member in the event of winding up is limited to £10. If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity. As a charity, tax exemption applies to income arising and expended on its charitable activities.
	An Independent Examination has been carried out on the accounts. There were no matters of concern arising as a result of the Examination.
	Its registered office is:
	86-90 Paul Street
	London
	EC2A 4NE